Randomized Controlled Study of Preventive Effect of TDX105 on Regorafenib Induced Dermatologic Toxicities

Cancer hosptial Chinese Academy of Medical Sciences0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Clinically confirmed colorectal cancer patients;
•2. It is planned to use the targeted drug regorafenib for the first time, and the initial dose is 120mg/d;
•3. PS score = 3;
•4. Aged = 18;
•5, no intellectual and mental disorders, normal language expression ability, ability to judge their own symptoms
•6. Understand and agree to accept the treatment, and sign the informed consent.

•1. Patients with skin reactions affected by simultaneous use of other targeted drugs (sorafenib, sunitinib, fruquintinib, etc.), chemotherapy drugs (capecitabine, doxorubicin, etc.) or hand-foot radiotherapy;
•2. Patients with skin diseases such as eczema, psoriasis and tinea pedis at observed skin sites (namely hands and feet); Patients with skin allergic diseases;
•3. Patients in the study who cannot cooperate with the continuation of this treatment;
•4. Sudden changes in the patient's condition affected and interfered with the researcher.

发起方

Cancer hosptial Chinese Academy of Medical Sciences